Literature DB >> 7349331

The pharmacokinetics of xylazine hydrochloride: an interspecific study.

R Garcia-Villar, P L Toutain, M Alvinerie, Y Ruckebusch.   

Abstract

The pharmacokinetic disposition of xylazine hydrochloride is described after both intravenous and intramuscular injection of a single dose, in four domestic species: horse, cattle, sheep and dog, by an original high performance liquid chromatographic technique. Remarkably small interspecific differences are reported. After intravenous administration, systemic half-life (t1/2 beta) ranged between 22 min (sheep) and 50 min (horse) while the distribution phase is transient with half-life (t1/2 alpha) ranging from 1.2 min (cattle) to 5.9 min (horse). The peak level of drug concentration in the plasma is reached after 12-14 min in all the species studied following intramuscular administration. Xylazine bioavailability, as measured by the ratios of the areas under the intravenous and intramuscular plasma concentration versus time curves, ranged from 52% to 90% in dog, 17% to 73% in sheep and 40% to 48% in horse. The low dosage in cattle did not permit calculation. Kinetic data are correlated with clinical data and the origins of interspecific differences are discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7349331     DOI: 10.1111/j.1365-2885.1981.tb00715.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  8 in total

1.  Effect of a short-term fast on ketamine-xylazine anesthesia in rats.

Authors:  Maggie B Struck; Karl A Andrutis; Harvey E Ramirez; August H Battles
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-05       Impact factor: 1.232

2.  Effects of anesthetic regimes on inflammatory responses in a rat model of acute lung injury.

Authors:  Spyridon Fortis; Peter M Spieth; Wei-Yang Lu; Matteo Parotto; Jack J Haitsma; Arthur S Slutsky; Nanshan Zhong; C David Mazer; Haibo Zhang
Journal:  Intensive Care Med       Date:  2012-06-19       Impact factor: 17.440

3.  Ketamine, Telazol, xylazine and detomidine. A comparative anesthetic drug combinations study in ponies.

Authors:  H C Lin; K R Branson; J C Thurmon; G J Benson; W J Tranquilli; W A Olson; A T Vähä-Vahe
Journal:  Acta Vet Scand       Date:  1992       Impact factor: 1.695

4.  Differences in Motor Evoked Potentials Induced in Rats by Transcranial Magnetic Stimulation under Two Separate Anesthetics: Implications for Plasticity Studies.

Authors:  Matthew Sykes; Natalie A Matheson; Philip W Brownjohn; Alexander D Tang; Jennifer Rodger; Jonathan B H Shemmell; John N J Reynolds
Journal:  Front Neural Circuits       Date:  2016-10-06       Impact factor: 3.492

5.  Quantification of horse plasma proteins altered by xylazine using the fluorogenic derivatization-liquid chromatography-tandem mass spectrometry.

Authors:  Miwako Mori; Tomoko Ichibangase; Shozo Yamashita; Isao Kijima-Suda; Masahiro Kawahara; Kazuhiro Imai
Journal:  J Equine Sci       Date:  2016-02-03

6.  Pharmacokinetic profile and partitioning in red blood cells of romifidine after single intravenous administration in the horse.

Authors:  Noemi Romagnoli; Khaled M Al-Qudah; Sara Armorini; Carlotta Lambertini; Anna Zaghini; Alessandro Spadari; Paola Roncada
Journal:  Vet Med Sci       Date:  2017-07-20

7.  Towards a fully automated surveillance of well-being status in laboratory mice using deep learning: Starting with facial expression analysis.

Authors:  Niek Andresen; Manuel Wöllhaf; Katharina Hohlbaum; Lars Lewejohann; Olaf Hellwich; Christa Thöne-Reineke; Vitaly Belik
Journal:  PLoS One       Date:  2020-04-15       Impact factor: 3.240

8.  Toxicokinetics of U-47700, tramadol, and their main metabolites in pigs following intravenous administration: is a multiple species allometric scaling approach useful for the extrapolation of toxicokinetic parameters to humans?

Authors:  Frederike Nordmeier; Iryna Sihinevich; Adrian A Doerr; Nadja Walle; Matthias W Laschke; Thorsten Lehr; Michael D Menger; Peter H Schmidt; Markus R Meyer; Nadine Schaefer
Journal:  Arch Toxicol       Date:  2021-10-03       Impact factor: 5.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.